Retatrutide Cost: 2026 Price Guide

Retatrutide is an investigational drug owned by Eli Lilly. As of 2026 it is in Phase 3 trials and has not received FDA approval for any use. A drug without approval has no list price, no pharmacy stock, and no insurance code. That is the entire reason pricing feels chaotic.

The numbers circulating online come from a separate market: vendors selling lyophilized (freeze-dried) retatrutide labeled "for research purposes only." These are not pharmaceutical products. They are not manufactured under the same oversight as an approved medication, and their purity and dose accuracy vary widely between sellers.

When retatrutide eventually clears FDA review, Eli Lilly will set a list price the same way it did for tirzepatide. At that point the cost structure will look completely different: a fixed monthly price, possible manufacturer savings cards, and eventual insurance negotiation. Until then, every "retatrutide cost" is a research-market estimate. See our retatrutide vs tirzepatide comparison for how the approved sibling drug is priced.

Research retatrutide is sold by total milligrams per vial, not by monthly supply. This is the single biggest source of confusion for newcomers comparing prices.

*Supply depends entirely on weekly dose. A 2 mg/week user gets far more weeks per vial than a 12 mg/week user.

Larger vials lower the per-milligram cost, which is why experienced users buy in bulk. But a larger vial also means more reconstituted peptide sitting in your fridge, and reconstituted retatrutide has a limited shelf life. Buying more than you can use before degradation wastes money. See how long reconstituted peptides last for storage timelines.

The price you pay per month is a function of your weekly dose, not the sticker price of the vial. A single 10 mg vial costs the same whether you stretch it over five weeks or ten.

Think of a retatrutide vial like a tank of fuel. The vial price is fixed, but how long it lasts depends entirely on how hard you run the engine. Clinical trials titrated retatrutide slowly, starting at 2 mg weekly and climbing toward 8-12 mg over months (Jastreboff et al., N Engl J Med, 2023).

Early titration months are cheap because doses are low. Costs climb sharply as you escalate. A person at a maintenance dose of 8-12 mg weekly can spend as much on research retatrutide as the projected retail price of approved Zepbound, but without the quality guarantees of an approved drug.

Use the retatrutide dosage calculator to map your protocol, and the peptide cost calculator to convert vial prices into a real monthly budget. For dosing logic, see our retatrutide dosage guide.

Research peptide prices move for reasons that have nothing to do with the molecule itself. Understanding the levers helps you spot a fair price from a gouge or a too-good-to-be-true scam.

Quantity discounts. Per-milligram cost drops steeply with vial size and multi-vial orders. This is the largest single factor.

Purity and testing. Vendors who publish third-party certificates of analysis (mass spectrometry and HPLC purity above 98%) charge more, and the premium is worth it. Untested cheap vials may be underdosed, degraded, or contaminated.

Synthesis difficulty. Retatrutide is a complex triple agonist, harder and more expensive to synthesize than simpler peptides like BPC-157. That floor keeps legitimate prices from dropping below a certain point.

Payment method and shipping. Crypto discounts, domestic versus international shipping, and cold-chain handling all shift the final number.

Demand spikes. When media coverage surges, prices rise. Retatrutide search volume climbed over 300% year over year, and vendor pricing tracks that attention.

A price far below the $13-per-mg floor is a warning sign, not a bargain. See where to buy peptides in 2026 for vendor evaluation criteria.

When retatrutide is approved, its price will almost certainly anchor to Eli Lilly's existing GLP-1 lineup rather than the research market. Tirzepatide, sold as Zepbound for weight loss, carries a list price near $1,060 per month before any discounts.

These are projections, not guarantees. Approval timing, label indications, and competitive pressure from other triple agonists will all shape the final number. Retatrutide showing up to 24% body-weight reduction in trials gives Lilly strong pricing power (Jastreboff et al., N Engl J Med, 2023).

The gap between projected retail ($1,000+) and current research pricing ($100-$300 at low doses) is exactly why the gray market exists. It is also why buyers accept the quality and legal risks. For the approved-drug pricing model, compare with how much is semaglutide and tirzepatide cost with insurance.

Most people pricing retatrutide are weighing it against approved or compounded alternatives. Here is how the monthly math compares at common maintenance doses.

Research retatrutide can look cheaper than approved drugs at low doses, but the comparison is not apples to apples. Approved and compounded products come from regulated supply chains with dose accuracy and sterility guarantees. Research vials do not. You are trading quality assurance for a lower sticker price.

Retatrutide's trial efficacy outpaced both tirzepatide and semaglutide on weight loss, which is the main reason interest is so high despite the lack of approval. For the head-to-head, see retatrutide vs tirzepatide and how does retatrutide work.

The vial price is only part of what you spend. Several recurring costs catch first-time buyers off guard.

Bacteriostatic water. Required to reconstitute the lyophilized powder. A multi-dose vial costs $3-$10 and is consumed across reconstitutions.

Syringes and needles. Insulin syringes run $15-$30 per box of 100. You replace them constantly.

Alcohol swabs and sharps disposal. Small but recurring.

Bloodwork. Responsible use means baseline and periodic labs. Out of pocket, a metabolic panel runs $50-$150.

Wasted product. Degraded peptide from poor storage, dosing errors, or buying more than you can use before expiration. This is the silent budget killer.

A realistic all-in monthly cost adds roughly $20-$40 of supplies on top of the vial cost, more if you factor in labs. Budget for the full kit, not just the peptide. Our retatrutide dosage guide and how to reconstitute retatrutide cover the supplies you need.

Mistake 1: Comparing vial price to monthly drug price. A $200 research vial is not "cheaper than Zepbound" until you calculate how many weeks it actually lasts at your dose. At high maintenance doses the math converges. The fix: always convert to cost-per-month using your real weekly dose.

Mistake 2: Chasing the lowest per-mg price. A vial priced well below $13 per mg is more likely underdosed or fake than a genuine bargain. The fix: prioritize third-party testing over price.

Mistake 3: Buying a 20 mg vial as a beginner. Large vials lower per-mg cost but reconstituted peptide degrades. If you cannot use it in time, you wasted money. The fix: match vial size to your realistic usage window.

Mistake 4: Ignoring supply and lab costs. The peptide is not the only expense. The fix: budget the full kit plus periodic bloodwork.

Mistake 5: Assuming insurance might help. No insurer covers an unapproved drug. The fix: treat retatrutide as a fully out-of-pocket cost until approval changes the picture.